# Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

> **NCT04718181** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 131 (actual)

## Conditions studied

- Muscular Atrophy, Spinal

## Interventions

- **DRUG:** risdiplam
- **DRUG:** omeprazole

## Key facts

- **NCT ID:** NCT04718181
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-01
- **Primary completion:** 2023-01-28
- **Final completion:** 2023-01-28
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2023-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04718181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04718181, "Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04718181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*